(Q42841521)
Statements
Molecular predictors of combination targeted therapies (cetuximab, bevacizumab) in irinotecan-refractory colorectal cancer (BOND-2 study) (English)
Heinz-Josef Lenz
Leonard Saltz
Wu Zhang
Mizutomo Azuma
Georg Lurje
Dongyun Yang
Alexandra Pohl
Yan Ning
Pierre Bohanes
Armin Gerger
Thomas Winder
Ellen Hollywood
Michael A. Gordon
Kathleen D. Danenberg